TheraRadar
← Back
Data updated: Jun 28, 2026

PRAXAIR DISTRIBUTION MID-ATLANTIC LLC

Pharma
Pharmaceuticals

PRAXAIR DISTRIBUTION MID-ATLANTIC LLC is a pharmaceutical company with 2 FDA-approved products.

2013
Since
2
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
2 Small Molecules

PRAXAIR DISTRIBUTION MID-ATLANTIC LLC's Key Drugs

PRAXAIR DISTRIBUTION MID-ATLANTIC LLC's core commercial portfolio centers on MEDICAL AIR, USP, HELIUM, USP — its most strategically important drugs approved in the last 15 years.

PRAXAIR DISTRIBUTION MID-ATLANTIC LLC's Recent FDA Approvals

PRAXAIR DISTRIBUTION MID-ATLANTIC LLC secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

PRAXAIR DISTRIBUTION MID-ATLANTIC LLC's Therapeutic Areas

Disease areas where PRAXAIR DISTRIBUTION MID-ATLANTIC LLC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

PRAXAIR DISTRIBUTION MID-ATLANTIC LLC Pipeline Snapshot

Active clinical trials for PRAXAIR DISTRIBUTION MID-ATLANTIC LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • MEDICAL AIR, USP leads revenue
  • 2 key drugs tracked

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling